Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.44 |
| ▸ | HTR2A | P28223 | 7/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13136748 | 0.86 | FFAR1 (0.44) | FFAR1NPSR1FFAR4HDAC6 | |
| SCHEMBL27387853 | 0.81 | NPSR1 (0.46) | FFAR1NPSR1FFAR4POLBHDAC6 | |
| SCHEMBL11259285 | 0.79 | GAA (0.49) | FFAR1NPSR1FFAR4POLBHDAC6 | |
| SCHEMBL7109335 | 0.79 | KCNH2 (0.46) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL11266144 | 0.79 | KDM4E (0.45) | FFAR1NPSR1FFAR4POLBHDAC6 | |
| SCHEMBL1197122 | 0.78 | IDO1 (0.47) | NPSR1 | |
| SCHEMBL13136705 | 0.78 | KEAP1 (0.48) | SLC6A4FFAR1NPSR1FFAR4SLC6A2 | |
| Hydrochloric Acid SCHEMBL3051856 | 0.78 | PLAU (0.44) | FFAR1NPSR1FFAR4POLBHDAC6 | |
| SCHEMBL9309798 | 0.78 | FFAR1 (0.47) | HTR2AFFAR1NPSR1FFAR4HDAC6 | |
| SCHEMBL10745896 | 0.77 | NPSR1 (0.63) | FFAR1NPSR1FFAR4POLBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | SLC6A4 114/4885KCNH2 1243/4885HTR2A 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.